Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

A study published in Brain Communications highlights a new approach to treating drug-resistant epilepsy. Researchers at Mayo Clinic have developed an innovative deep brain stimulation (DBS) platform ...

Tesla (T) magnetic resonance imaging (MRI) changes management in more than half of adult candidates for epilepsy surgery.

The effect of levetiracetam on high-frequency oscillations in patients with AD and epilepsy shows its potential as a biomarker for disease detection.

The MRI-guided technique allows surgeons to access deeper brain regions. Australia’s The Alfred is the first hospital in Victoria to introduce laser interstitial thermal therapy for epilepsy surgery.

Proceeds from the financing will be used to advance the company’s wholly owned pipeline of allogeneic cell therapy candidates ... mesial temporal lobe epilepsy (MTLE), which is among the most ...

Mar. 25, 2025 — A drug typically prescribed for arthritis halts brain-damaging seizures in mice that have a condition like epilepsy, according to researchers. If the drug proves viable for human ...

follows continued positive clinical signal from Neurona's ongoing Phase 1/2 clinical trial - The round recognizes recent FDA alignment to advance NRTX-1001 into the Phase 3 EPIC (EPIlepsy Cell therapy ...

A study published in Brain Communications highlights a new approach to treating drug-resistant epilepsy. Researchers at Mayo Clinic have developed an innovative deep brain stimulation (DBS) platform ...

Mesial temporal lobe epilepsy is the most common form of epilepsy. Credit: PonyWang via Getty Images. Neurona Therapeutics has gained $102m to support the advancement of its investigational cell ...